Pain therapeutics startup Wholeleaf set to secure additional investments
Pain management startup Institutional investors IPV and Benzai 10 Capital are in advanced negotiations with Wholeleaf to raise Rs 7.5 crore in a new fundraising round.
The Gurugram-based firm raised a another Rs 3.5 crore from Ah before securing Rs 1.5 crore in a seed round earlier this year from investors on Shark Tank India, including Aman Gupta, Kanika Tekriwal, and Namita Thapar. angel and venture capitalists. Thus far, the company has raised Rs 5 crore.
The money raised will be used to improve brand visibility in both online and offline channels, increase product development, scale distribution, and accelerate the expansion of physical retail presence.
Wholeleaf is a natural pain relief firm with a medical focus that was founded in 2021 by Shivraj Sharma. It presently holds the top spot in India’s cannabinoid pain treatments market and is committed to creating long-term, safe, and effective solutions for managing neuropathic and chronic pain.
With a line of oral tinctures and topical formulations that treat ailments like migraines, arthritis, fibromyalgia, menstrual pain, anxiety, and insomnia, the company presently works in the chronic pain treatment market. Additionally, the business is developing a pipeline of remedies for persistent neuropathic pain.
Wholeleaf says that it currently reports an ARR of Rs 18 crore and claims strong penetration within its category, supported by a structured, physician-led product development approach. Each formulation goes through multi-stage validation, including safety testing, pilot studies, and third-party government-certified laboratory assessments.
According to Wholeleaf, it is present in about 2,000 retail locations, mostly in the Delhi-NCR area, and it intends to grow to 5,000–7,000 locations this year. Bengaluru, Mumbai, Hyderabad, Kolkata, Ahmedabad, Goa, and Chennai are among the tier I and tier II cities where the company hopes to expand.
With a disciplined, physician-led approach to product development, Wholeleaf claims strong penetration within its category and now reports an ARR of Rs 18 crore. Every formulation undergoes a multi-phase validation process that includes pilot studies, safety testing, and evaluations from independent, government-approved laboratories.
“We are raising this round at a crucial juncture of the business, where the focus is on both, growth and building sustainable product infrastructure for scale. In a category like pain therapeutics, future success hinges on regulatory discipline, medical trust and distribution depth, and that is exactly what we are building for over the next phase of growth,” said Shivraj Sharma, founder and CEO, Wholeleaf.
